A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
Interventions: irinotecan, oxaliplatin, capecitabine, bevacizumab Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized
创建时间：
2014-12-15
